<DOC>
	<DOCNO>NCT00181727</DOCNO>
	<brief_summary>This open-labeled study Divalproex Sodium Extended Release ( Depakote ER ) , test efficacy treatment mania child age 6-12 diagnosed Bipolar I , Bipolar II , Bipolar Spectrum Disorders . This exploratory , pilot study , seek determine whether Divalproex Sodium Extended Release efficacious well tolerate treatment youth pediatric bipolar bipolar spectrum disorder , study result use generate hypothesis large randomize control clinical trial explicit hypotheses sufficient statistical power .</brief_summary>
	<brief_title>Study Depakote ER Treatment Mania Children Ages 6-12 With Bipolar Disorder</brief_title>
	<detailed_description>Initial clinical evidence suggest Divalproex Sodium may play therapeutic role management pediatric bipolar disorder . Its new Extended Release formulation offer advantage day dose . Although precise mechanism Divalproex Sodium exert therapeutic effect remain unknown , suggested activity may relate increase brain concentration gamma-aminobutyric acid ( GABA ) . Although short act formulation Divalproex Sodium FDA approve treatment adult bipolar disorder , Extended Release formulation currently FDA approve adult prophylactic treatment migraine headache yet study patient mania . Three study Divalproex Sodium document safety efficacy compound , well superiority placebo , treatment adult bipolar disorder . This medication , however , adequately investigated child . The propose study include 1 ) 8-week acute period , participant observe weekly visit , 8-month extension period , participant see study clinician monthly basis , document response rate 2 ) assessment impact Divalproex Sodium Extended Release functional capacity ( quality life , psychosocial function ) cognition , 3 ) careful assessment safety tolerability .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Male female subject , 612 year age . 2 . Subjects must DSMIV diagnosis bipolar I , bipolar II disorder bipolar spectrum disorder currently display manic , hypomanic , mixed symptom ( without psychotic feature ) accord DSMIV base clinical assessment confirm structured diagnostic interview ( Kidd Schedule Affective Disorders Schizophrenia Epidemiological Version ) ( Kaufman , Birmaher et al . 1997 ) . Bipolar spectrum disorder ( subthreshold bipolar disorder ) operationalized severe mood disturbance , meet DSMIV Criteria A bipolar disorder meet few element criterion B ( require 2 item elation category 3 irritability ) . 3 . Subjects legal representative must level understanding sufficient communicate intelligently investigator study coordinator , cooperate test examination require protocol . 4 . Subjects legal representative must consider reliable . 5 . Each subject his/her authorized legal representative must understand nature study . The subject 's authorized legal representative must sign informed consent document subject must sign informed assent document . 6 . Subjects must initial score YMRS total score least 20 . 7 . Subject must able participate mandatory blood draw . 8 . Subject must able swallow pill . 9 . Subjects comorbid ADHD , ODD , CD , anxiety depressive disorder allow participate study provide meet exclusionary criterion . 10 . For concomitant stimulant therapy use treat ADHD , subject must stable dose medication 1 month prior study enrollment . The dose stimulant therapy change throughout duration initial phase study . 1 . Investigator his/her immediate family ; define investigator 's spouse , parent , child , grandparent , grandchild . 2 . Serious , unstable illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease . 3 . Uncorrected hypothyroidism hyperthyroidism . 4 . History severe allergy multiple adverse drug reaction . 5 . Nonfebrile seizure without clear resolve etiology . 6 . Leukopenia history leukopenia without clear resolve etiology . 7 . DSMIV substance ( except nicotine caffeine ) dependence within past 6 month . 8 . Judged clinically serious suicidal risk . 9 . Any concomitant medication primarily central nervous system activity specify Concomitant Medication portion protocol . 10 . A nonresponder history intolerance Divalproex Sodium Extended Release adequate trial ( 2 month adequate dose ) determine clinician . 11 . Receiving treatment Strattera . 12 . Current diagnosis schizophrenia . 13 . Pregnant nursing female . 14 . Non English speaking subject allow study follow reason : ) assessment instrument available adequately standardized language ; b ) clinical trial facility locate Cambridge MGH main campus without availability translator ; c ) psychiatric questionnaire evaluation tax add complexity translator potential make patient experience even exhaust .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>mania</keyword>
	<keyword>depakote ER</keyword>
	<keyword>child</keyword>
</DOC>